Legal Showdown on Tariff Powers Looms

President Donald Trump’s sweeping use of tariffs has been a defining feature of his administration’s approach to foreign policy and economic strategy. However, this strategy is now facing escalating legal challenges, with the Supreme Court set to review crucial elements of Trump’s tariff authority in its upcoming session. The White House appears to be preemptively adapting its tactics, seeking to preserve its expansive use of trade barriers regardless of the judicial outcome, leading to heightened uncertainty for businesses both in the United States and abroad.

The central issue at stake involves the distinction between Trump’s reliance on Section 232 of the Trade Expansion Act of 1962—which allows tariffs on the grounds of national security—and his controversial application of the International Emergency Economic Powers Act (IEEPA) of 1977. While the Supreme Court weighs whether broad-based tariffs under IEEPA will stand, the administration is intensifying its use of Section 232, a more legally robust and time-tested authority.

Tariffs have been imposed or proposed in recent months on sectors spanning steel, aluminum, semiconductors, pharmaceuticals, and even furniture, with rates ranging dramatically from 25% to as high as 100% on select goods. Legal observers note that shifting tariff authorities is likely to maintain a high level of unpredictability for global supply chains and investment planning.

Business on Edge as Supreme Court Deliberates

The ramifications of the upcoming Supreme Court hearing are significant. The justices are scheduled to hear arguments on November 5, with a decision likely by year’s end. A ruling could either uphold the administration’s sweeping use of IEEPA, or curtail those powers, potentially forcing the White House to issue refunds for previously collected tariffs.

In anticipation of potential legal setbacks, Trump’s team has expanded its reliance on actions that fall under Section 232, pursuing new tariffs on a widening roster of industries. According to Natasha Sarin of Yale’s Budget Lab, “even a Supreme Court ruling against the administration is unlikely to end tariff-driven uncertainty, as the White House is likely to pivot rapidly to other legal grounds.”

Brian Gardner, Chief Washington Policy Strategist at Stifel, told Yahoo Finance that clarity is unlikely in the short term: “We don’t know exactly what Plan B is yet. But tariffs are now a central tool of the administration’s foreign policy—and that is unlikely to change, regardless of legal outcomes.”

As a result, business executives, trade groups, and investors are bracing for an unpredictable environment throughout 2025 and into 2026.

Tariffs on the Horizon: Semiconductors and Manufacturing

The next major test could be the long-anticipated tariffs on semiconductors—a move closely watched by technology firms and global investors. With the U.S. and China scheduled to resume high-level trade talks later this month, the prospect of new levies on a sector critical for everything from automobiles to artificial intelligence is sending ripples through global markets.

The Bureau of Industry and Security is already conducting multiple Section 232 investigations across areas such as critical minerals, robotics, medical devices, and personal protective equipment. Even as the recent government shutdown threatened federal activity, the Trump administration labeled tariff investigations as ‘essential government functions,’ ensuring their momentum continues even during periods of fiscal gridlock in Washington.

For American manufacturers, the possibility of on-again, off-again duties poses serious challenges. “The challenge with tariffs is they create a ton of uncertainty,” Sarin reemphasized, a sentiment echoed by trade and industry representatives across the country.

Pharmaceutical Tariffs: Exemptions Abound, Uncertainty Reigns

This evolving approach was starkly demonstrated in Trump’s recent handling of pharmaceutical tariffs. In the summer of 2025, the administration signaled it would slap duties of up to 200% on imported drugs, only to revise the figure to 100%, and then roll out a succession of exemptions. Major pharmaceutical firms manufacturing domestically were excluded from tariffs, as were producers in U.S. trade partner countries.

The uncertainty peaked when, earlier this week, Trump granted Pfizer a three-year exemption from tariffs as part of a deal that saw the company agree to lower Medicaid drug prices. Commerce Secretary Howard Lutnick hinted that similar exceptions would be considered for other firms as negotiations progress: “While we are negotiating with these companies, we’re going to let the talks play out,” he told reporters, effectively putting enforcement of pharma tariffs on pause and opening the door to more case-by-case treatment.

The pharmaceutical sector’s reaction has been revealing: in light of the volatility, investors drove drugmaker stocks to their best week in 16 years. This underscores how political maneuvering and regulatory uncertainty can catalyze unexpected market gains, even as companies express concern over longer-term planning.

Looking Ahead: Investor Takeaways and Strategic Uncertainty

While some see the unpredictability as detrimental, others are looking for opportunities amidst the chaos. The Trump administration’s willingness to negotiate exemptions and tailor tariffs to individual companies or sectors is reminiscent of earlier trade war tactics, but further complicates an already complex regulatory environment. Manufacturers, importers, and multinational now face difficult choices over supply chains, investment commitments, and pricing strategies, often with little notice or clarity on future rules.

Meanwhile, the broader geopolitical implications remain profound. As the U.S. adopts a more assertive and unpredictable stance in trade negotiations—not only with China, but with other partners—analysts warn of potential retaliatory measures, increased costs passed on to consumers, and disruptions in global supply chains.

With the Supreme Court’s decision looming and the 2026 election cycle already influencing economic and foreign policy, one thing is clear: tariff-induced uncertainty is here to stay. Savvy business leaders and investors will need to monitor legal, political, and international developments closely, while building flexibility into their operations and portfolios.

Stay tuned to Yahoo Finance for ongoing updates as this critical story develops and shapes the future of U.S. and global markets.